EUCTR2014-005490-37-AT进行中（未招募）1 期
A PHASE III, MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH NAB-PACLITAXEL COMPARED WITH PLACEBO WITH NAB-PACLITAXEL FOR PATIENTS WITH PREVIOUSLY UNTREATED METASTATIC TRIPLE-NEGATIVE BREAST CANCER
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 902
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Women aged = 18 years
- •Metastatic or locally advanced, histologically documented TNBC (absence of HER2, ER, and PR expression)
- •No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC
- •Representative FFPE tumor specimens in paraffin blocks (preferred) or at least
- •15 unstained slides, with an associated pathology report documenting ER, PR, and HER2 negativity
- •A tumor specimen obtained from metastatic or locally advanced disease (if applicable) must be submitted if clinically feasible
- •ECOG performance status of 0 or 1
- •Life expectancy = 12 weeks
- •Measurable disease, as defined by RECIST v1.1
- •Adequate hematologic and end-organ function defined by laboratory results obtained within 2 weeks prior to first study treatment.
- •Women of child bearing potential must agree to use adequate contraception (double barrier
- •methods of birth control or abstinence) prior to study entry, for the duration of study treatment, and for at least 5 months after the last dose of study treatment.
- •Patients who are not postmenopausal (= 12 months of non-therapy-induced amenorrhea) or surgically sterile must have a negative serum pregnancy test result within 14 days prior to initiation of study drug
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 540
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 360
排除标准
- •Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for > 2 weeks prior to randomization
- •Known CNS disease, except for treated asymptomatic CNS metastases
- •Leptomeningeal disease
- •Uncontrolled pleural effusion, pericardial effusion, or ascites (indwelling drainage catheters are permitted)
- •Uncontrolled tumor-related pain
- •Uncontrolled hypercalcemia
- •Pregnancy or lactation
- •Evidence of significant uncontrolled concomitant disease that could affect compliance with the protocol or interpretation of results, including significant liver disease (such as cirrhosis, uncontrolled major seizure disorder, or superior vena cava syndrome)
- •Significant cardiovascular disease
- •Severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
- •History of autoimmune disease (Autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone and Type 1 diabetes mellitus on an stable insulin regimen may be eligible for this study)
- •Prior allogeneic stem cell or solid organ transplantation
- •History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- •Positive test for HIV
- •Active hepatitis B or hepatitis C
- •Active tuberculosis
- •Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial.
- •Low dose steroids for nausea, adrenocortical insufficiency or orthostatic hypotension, IV contrast allergic reactions and inhaled corticosteroids are permitted.
研究者
相似试验
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-DEF. Hoffmann-La Roche Ltd900
进行中（未招募）
不适用
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 18.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-ESRoche Farma S.A. que representa en España a F. Hoffmann-La Roche Ltd350
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-SIF. Hoffmann-La Roche Ltd902
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 19.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-DKF. Hoffmann-La Roche Ltd902
进行中（未招募）
1 期
A trial of MPDL3280A and nab-Paclitaxel in metastatic triple negative breast cancerPreviously untreated metastatic triple negative breast cancerMedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 100000004864EUCTR2014-005490-37-LVF. Hoffmann-La Roche Ltd902